David Chang

Dr. David Chang, Chief Executive Officer at WuXi Advanced Therapies and OXGENE, holds a wealth of experience in the cell and gene therapy industry, including biopharmaceutical technical development, manufacturing operations, engineering, and strategy. Prior to joining WuXi Advanced Therapies, David held the role of Corporate Vice President and Head of Cell Therapy Global Manufacturing at Celgene Corporation, a Bristol-Myers Squibb Company, where he oversaw the global CAR-T manufacturing network and technologies. David earned a bachelor’s in chemical engineering from National Taiwan University and holds a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology.